文献速递儿科与产科急症消化、代谢与肾脏急症

丹麦儿童和青少年感染SARS-CoV-2后不良事件风险及BNT162b2在青少年中的效果:队列研究

Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study.
PubMed 文献 · BMJ · 2022-04-11
一句话结论丹麦全国队列显示儿童青少年SARS-CoV-2感染后绝对不良事件风险总体较低,但MIS-C发生率为0.05%(32/70 666);BNT162b2在delta变异占优势期间似乎可有效降低青少年感染风险。

该研究基于丹麦全国医疗登记数据,纳入至2021年10月1日所有<18岁接受SARS-CoV-2 RT-PCR检测或接种BNT162b2的儿童和青少年。991 682名受检者中74 611人(7.5%)阳性;阳性者30天内住院(≥12小时)风险0.49%(361/74 350),ICU入住风险0.01%(10/73 187),感染后2个月内MIS-C风险0.05%(32/70 666),MIS-C以外心肌炎、脑炎均无报告,吉兰-巴雷综合征少于5例。感染后1–6个月阳性者全科医生接触率较参考队列增加1.08倍(95%CI 1.06–1.10)。278 649名青少年接种BNT162b2,在delta为主要变异期间,与未接种同龄人相比,接种一剂者20天后估计疫苗有效性62%(95%CI 59%–65%),接种两剂者60天后为93%(95%CI 92%–94%)。

要点

  • 丹麦<18岁RT-PCR阳性儿童青少年30天内住院(≥12小时)风险0.49%(361/74 350),ICU入住风险0.01%(10/73 187)。
  • SARS-CoV-2感染后2个月内MIS-C风险0.05%(32/70 666);MIS-C以外心肌炎、脑炎无报告,吉兰-巴雷综合征少于5例。
  • 感染后1–6个月,阳性者全科医生接触率较参考队列增加1.08倍(95%CI 1.06–1.10),可能提示持续症状。
  • delta为主要变异期间,青少年接种一剂BNT162b2后20天疫苗有效性62%(95%CI 59%–65%),接种两剂后60天为93%(95%CI 92%–94%)。

适用人群与场景

  • 丹麦全国所有<18岁、截至2021年10月1日接受SARS-CoV-2 RT-PCR检测或接种BNT162b2的儿童和青少年。
  • 疫苗有效性分析人群为接种BNT162b2的青少年,与未接种同龄人比较。

研究设计与关键结果

  • 研究类型为队列研究,基于丹麦全国医疗登记数据;991 682名儿童和青少年接受SARS-CoV-2 RT-PCR检测,其中74 611人(7.5%)阳性。
  • 任何变异感染后30天内住院(任何≥12小时的医院接触)风险为0.49%(95%CI 0.44%–0.54%;361/74 350),ICU入住风险为0.01%(95%CI 0.01%–0.03%;10/73 187)。
  • SARS-CoV-2感染后2个月内MIS-C风险为0.05%(95%CI 0.03%–0.06%;32/70 666);MIS-C以外无心肌炎、无脑炎,吉兰-巴雷综合征少于5例。
  • 感染后急性期后(1–6个月),SARS-CoV-2阳性者全科医生接触率较研究期间所有受检儿童中采样的参考队列增加1.08倍(95%CI 1.06–1.10)。
  • 共278 649名青少年接种BNT162b2;在delta为主要变异期间,与未接种青少年相比,229 799名接种一剂者20天后估计疫苗有效性为62%(95%CI 59%–65%),175 176名接种两剂者60天后为93%(95%CI 92%–94%)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 丹麦儿童和青少年SARS-CoV-2感染后不良事件绝对风险总体较低,但MIS-C发生率为0.05%(32/70 666)。
  • 调整分析中SARS-CoV-2阳性儿童和青少年全科医生就诊率轻度增加,可能提示持续症状。
  • 作者认为BNT162b2似乎可有效降低青少年delta变异SARS-CoV-2感染风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess the risk of acute and post-acute adverse events after SARS-CoV-2 infection in children and adolescents in Denmark and to evaluate the real world effectiveness of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) among adolescents.

DESIGN: Cohort study.

SETTING: Nationwide Danish healthcare registers.

PARTICIPANTS: All Danish people younger than 18 years who were either tested for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) or vaccinated with BNT162b2 to 1 October 2021.

MAIN OUTCOME MEASURES: Risk of hospital admissions (any hospital contact of ≥12 hours); intensive care unit (ICU) admissions; serious complications, including multisystem inflammatory syndrome in children (MIS-C), myocarditis, and neuroimmune disorders; and initiating drug treatment and health service use up to six months after being tested. Vaccine effectiveness in vaccine recipients compared with unvaccinated peers was evaluated as one minus the risk ratio at 20 days after the first dose and 60 days after the second dose.

RESULTS: Of 991 682 children and adolescents tested for SARS-CoV-2 using RT-PCR in Denmark, 74 611 (7.5%) were positive. The risk of hospital admission with any variant for ≥12 hours was 0.49% (95% confidence interval 0.44% to 0.54%; 361/74 350), and 0.01% (0.01% to 0.03%; 10/73 187) of participants were admitted to an ICU within 30 days of testing positive. The risk of MIS-C within two months of SARS-CoV-2 infection was 0.05% (0.03% to 0.06%; 32/70 666), whereas no participants had myocarditis outside of MIS-C or encephalitis and fewer than five had Guillain-Barré syndrome. In the post-acute phase (1-6 months after infection), participants who tested positive for SARS-CoV-2 showed a 1.08-fold (95% confidence interval 1.06-fold to 1.10-fold) increase in rate of contacts with general practitioners compared with a reference cohort sampled among all children tested for SARS-CoV-2 during the study period. Overall, 278 649 adolescents received BNT162b2. Compared with unvaccinated adolescents, the estimated vaccine effectiveness among 229 799 adolescents vaccinated with one dose was 62% (95% confidence interval 59% to 65%) after 20 days, and among 175 176 vaccinated with two doses was 93% (92% to 94%) after 60 days during a period when delta was the dominant variant.

CONCLUSIONS: The absolute risks of adverse events after SARS-CoV-2 infection were generally low in Danish children and adolescents, although MIS-C occurred in 0.05% (32/70 666) of participants with RT-PCR confirmed SARS-CoV-2 infection. In adjusted analyses, rates of general practitioner visits were slightly increased in SARS-CoV-2 positive children and adolescents, which could indicate persisting symptoms. BNT162b2 appeared to be effective in reducing the risk of SARS-CoV-2 infection with the delta variant in adolescents.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Kildegaard H, Lund LC, Højlund M, et al. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. BMJ. 2022. PMID: 35410884. doi:10.1136/bmj-2021-068898

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。